Prior authorization for a GLP-1, and what a denial actually turns on
Most GLP-1 denials aren't decisions about you. Federal law lets a drug plan exclude agents used for weight loss as a category, and Medicare Part D adopts that exclusion by reference — so for a weight-loss prescription the exceptions process is closed before it starts. Where a drug is covered, prior authorization is a separate machine with its own deadlines, and missing one of them is itself a denial you can appeal.
What this comes down to
- Federal law lists agents used for anorexia, weight loss, or weight gain among the drug classes a plan may exclude. Part D's definition of a covered drug adopts that list as it stood on December 8, 2003.
- The exceptions process cannot be used to obtain a drug that is not a Part D drug at all. That is the sentence most weight-loss denials rest on.
- A standard coverage determination is due in 72 hours; an expedited one in 24. If the plan misses the deadline, the regulation says the failure is itself an adverse determination and the request goes to an independent reviewer.
- Among Medicare Part D plans that covered them, prior authorization sat below 25% until 2023 and reached about 83% by the third quarter of 2024.
The exclusion that decides most of these before anyone reads your chart
The Medicaid statute lists the drug classes a plan may exclude or restrict, and the first item on that list is agents when used for anorexia, weight loss, or weight gain[1]. Medicare Part D then defines a covered drug by pointing at that same list as it stood on December 8, 2003[2]. The consequence is blunt: a GLP-1 prescribed for weight loss can sit outside the benefit entirely, while the identical molecule prescribed for type 2 diabetes does not.
The regulation governing exceptions says nothing in it may be construed to let an enrollee use the exceptions process to request or be granted coverage for a prescription drug that does not meet the definition of a Part D drug. So where the exclusion applies, a perfect supporting statement from a perfect prescriber changes nothing. That's worth knowing before you spend three weeks on one.
Where the drug is covered, prior authorization is the gate
Prior authorization is approval from a health plan that may be required before you fill a prescription in order for it to be covered[7]. It isn't a clinical judgment about whether the drug works; it's a check that your case matches criteria the plan wrote down.
It has also become close to universal in this class. A 2025 cross-sectional study of quarterly Medicare formulary files — 54,358 Medicare Advantage and 15,895 standalone plan-quarter observations — found prior authorization below 25% among covering plans until the third quarter of 2023, then rising to 83.6%, 83.2% and 83.0% by the third quarter of 2024 for injectable semaglutide, injectable tirzepatide and oral semaglutide[6]. Coverage widened and the gate went up at the same time.
PubMed, via the E-utilities API
"prior authorization"[tiab] AND (semaglutide[tiab] OR tirzepatide[tiab] OR "GLP-1"[tiab] OR "glucagon-like peptide-1"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 0. Positive control — semaglutide, identical trial filter — returned 306 through the identical filter in the same session.
Unfiltered, prior authorization alongside a GLP-1 term returns 18 records in total, and they are cross-sectional studies, policy reviews and case reports. Nobody has randomized the process. The control shows the filter finds trials of this molecule readily — 306 — so the zero describes the subject, not the search.
What a denial turns on, in the plan's own terms
For a formulary exception — a drug the plan does not otherwise cover — the regulation requires the prescriber to state that all of the covered drugs on any tier for the same condition would not be as effective for you as the requested drug, would have adverse effects for you, or both[3]. For a step-therapy or tiering exception the requirement is narrower but the same in shape: the preferred drug would not be as effective, or would have adverse effects, or both.
“Nothing in this section should be construed to mean that the physician's or other prescriber's supporting statement required for an exceptions request will result in an automatic favorable decision.”
[3]
That sentence is in the regulation for a reason. The supporting statement starts the clock and satisfies a requirement; it doesn't decide the outcome. What decides the outcome is whether your documented history matches the criteria the plan published — which is why the single most useful thing to ask for, before anything else, is the plan's written criteria for that drug.
The deadlines, and the one that works in your favor
| Request | Deadline | What happens if the plan misses it |
|---|---|---|
| Standard determination | No later than 72 hours after the request | The failure is an adverse coverage determination and the request goes to the independent review entity within 24 hours |
| Expedited determination | No later than 24 hours after the request | Same: the failure is itself an adverse determination and the case is forwarded |
| Exception request | 72 hours from the prescriber's supporting statement, or 24 expedited | If no supporting statement arrives within 14 calendar days, the clock starts anyway at the end of those 14 days |
| Request for payment | 14 calendar days after the request | Handled as a payment determination |
Medicare Part D coverage determinations, read from the Code of Federal Regulations as displayed on 2026-09-10.
The missed-deadline rule is the part most people never use[4][5]. A plan that simply doesn't answer has, by regulation, denied you — and the denial is appealable to a reviewer who does not work for the plan. Silence isn't a state you have to wait out.
What people do instead, and what it costs
When the exclusion applies, the question stops being about coverage and becomes about cash. On our own roster, 71 brand GLP-1 prices across 26 sellers run from $25 to $1899 a month, and 531 compounded prices across 160 sellers have a middle of $199[8]. The cash range in full is the companion to this page, and the calculator adds a membership fee to a medication price over the months you expect to take it.
Where the money comes from matters too. What the IRS publications say about HSA and FSA money turns on whether a physician diagnosed a specific disease — the same fact the plan was asking about, arriving from a different direction.
The exclusion is about the drug's use, not its name. A plan that will not cover a GLP-1 for weight loss may cover the same molecule for type 2 diabetes or for cardiovascular risk reduction, because those are different medically accepted indications. That is a conversation with a prescriber about your actual diagnosis, not a workaround, and nobody here holds a license to advise you on it.
And if you do end up paying cash through a telehealth company, the thing that determines whether you can stop is not the price. It is what the company's own terms say about cancellation, which is a document almost nobody reads before the card goes in.
Questions people actually ask
Why does my insurance cover Ozempic but not Wegovy?
Usually because the plan is covering an indication rather than a molecule. Federal law lets a drug plan exclude agents used for weight loss as a category, and Medicare Part D adopts that exclusion by reference, so the same active ingredient can be covered for type 2 diabetes and excluded for weight management under one plan.
How long does a GLP-1 prior authorization take?
Under the Medicare Part D rules, a standard coverage determination is due no later than 72 hours after the request and an expedited one no later than 24 hours. For an exception, the clock runs from the prescriber's supporting statement, and if none arrives within 14 calendar days the plan must decide anyway.
Can I appeal a GLP-1 denial?
Yes, and there is one route people miss: if the plan does not answer within its deadline, the regulation treats that failure as an adverse coverage determination and requires the plan to forward your request to an independent review entity within 24 hours. A non-answer is appealable.
Will a letter of medical necessity get a weight-loss GLP-1 covered?
Not where the categorical exclusion applies. The regulation says the exceptions process may not be used to obtain coverage for a drug that does not meet the definition of a Part D drug at all, and it separately says a prescriber's supporting statement never produces an automatic favorable decision.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.42 U.S.C. §1396r-8 — Payment for covered outpatient drugs. Office of the Law Revision Counsel, United States Code, 2026. Source · Document dated September 2026Subsection (d)(2) lists the drugs or classes of drugs whose medical uses may be excluded from coverage or otherwise restricted, and item (A) on that list is agents when used for anorexia, weight loss, or weight gain. The page states the text contains laws in effect on September 10, 2026.
- 2.42 U.S.C. §1395w-102 — Prescription drug benefits. Office of the Law Revision Counsel, United States Code, 2026. Source · Document dated September 2026Subsection (e)(2)(A) excludes from the term covered part D drug those drugs or classes of drugs, or their medical uses, that may be excluded or restricted under section 1396r-8(d)(2) as those sections were in effect on December 8, 2003, with named carve-outs for smoking cessation agents, certain barbiturates and benzodiazepines.
- 3.42 CFR §423.578 — Exceptions process. Electronic Code of Federal Regulations, 2026. Source · Document dated September 2026The prescriber's supporting statement requirements for tiering and formulary exceptions; the statement that nothing in the section allows the exceptions process to be used for a drug that does not meet the definition of a Part D drug; and the statement, quoted verbatim, that a supporting statement will not result in an automatic favorable decision. The eCFR displayed title 42 as up to date as of 9/10/2026, last amended 8/13/2026.
- 4.42 CFR §423.568 — Standard timeframe and notice requirements for coverage determinations. Electronic Code of Federal Regulations, 2026. Source · Document dated September 2026A determination on a drug benefit request no later than 72 hours after receipt; for an exception, 72 hours from the prescriber's supporting statement, or from the end of 14 calendar days if none is received; payment requests within 14 calendar days; and that failing the deadline constitutes an adverse coverage determination which must be forwarded to the independent review entity within 24 hours.
- 5.42 CFR §423.572 — Expedited coverage determinations. Electronic Code of Federal Regulations, 2026. Source · Document dated September 2026An expedited determination no later than 24 hours after receiving the request, and the same rule that missing the timeframe is itself an adverse coverage determination to be forwarded within 24 hours.
- 6.Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open, 2025. PMID 40880091 · doi:10.1001/jamanetworkopen.2025.29842A cross-sectional study of quarterly CMS formulary files covering 54,358 Medicare Advantage and 15,895 standalone plan-quarter observations, reporting prior authorization below 25% among covering plans until 2023 Q3 and 83.6%, 83.2% and 83.0% by 2024 Q3 for injectable semaglutide, injectable tirzepatide and oral semaglutide.
- 7.Prior authorization — glossary. HealthCare.gov, U.S. Centers for Medicare & Medicaid Services, 2026. SourcePrior authorization is approval from a health plan that may be required before you get a service or fill a prescription in order for it to be covered by the plan.
- 8.The Telehealth Graded price record. Telehealth Graded, 2026. SourceThe brand and compounded price ranges quoted here are computed at build time from the site's own price records, each read off the seller's own page and stamped with the day we read it.
Key figures